Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Viracta Therapeutics Inc VIRX

Healthcare Biotechnology
Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers, which impact patients worldwide. The Company’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated... see more

Recent & Breaking News (NDAQ:VIRX)

Viracta Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire November 2, 2022

Viracta Therapeutics Announces New Employment Inducement Grant

GlobeNewswire September 19, 2022

Viracta Therapeutics Announces Chief Executive Officer Leadership Succession to Drive the Next Phase of the Company's Strategic Development and Growth

PR Newswire September 19, 2022

Viracta Therapeutics Announces Orphan Drug Designation Granted by the European Commission for Nana-val for the Treatment of Peripheral T-cell Lymphoma

PR Newswire September 7, 2022

Viracta Therapeutics Chief Scientific Officer, Dr. Ayman Elguindy, Elected to the Governing Board of the International Association for Research on Epstein-Barr Virus and Associated Diseases

PR Newswire August 16, 2022

Viracta Therapeutics Appoints Jane Chung, R.Ph., to its Board of Directors

PR Newswire August 11, 2022

Viracta Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates

PR Newswire August 9, 2022

Viracta Therapeutics President and Chief Executive Officer Dr. Ivor Royston Receives the Science History Institute's Biotechnology Heritage Award

PR Newswire June 13, 2022

Viracta Therapeutics Provides an Update on the Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors and Announces Upcoming Poster Presentation at the ASCO Annual Meeting

PR Newswire June 2, 2022

Viracta Therapeutics to Present at the Jefferies Healthcare Conference

PR Newswire June 1, 2022

Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman

GlobeNewswire May 23, 2022

Viracta Therapeutics Announces New Employment Inducement Grant

PR Newswire May 13, 2022

Viracta Therapeutics to Present at Upcoming May Investor Conferences

PR Newswire May 11, 2022

Viracta Therapeutics Reports First Quarter 2022 Financial Results and Recent Updates

PR Newswire May 10, 2022

Viracta Therapeutics to Host Key Opinion Leader Webinar on Nana-val for the Treatment of Advanced Epstein-Barr Virus-Positive Solid Tumors

PR Newswire April 20, 2022

Viracta Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

PR Newswire April 7, 2022

Viracta Therapeutics Announces New Employment Inducement Grant

PR Newswire March 18, 2022

Viracta Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference

PR Newswire March 9, 2022

Viracta Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

PR Newswire February 10, 2022

Viracta Therapeutics Announces First Patient Dosed in Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-Barr Virus-Positive Solid Tumors

PR Newswire January 31, 2022